mProX™ Human MRGPRX4 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- GPCR Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human MRGPRX4 Stable Cell Line (S01YF-0923-PY112). Click the button above to contact us or submit your feedback about this product.
Michael (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Emily (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Established HTLA cells with stable expression of FLAG-tagged MRGPRX4-Tango and verified cell surface receptor presence via flow cytometric analysis.
Untransfected (HTLA) and stably transfected HTLA-MRGPRX4-Tango (HTLA-MRGPRX4) cells underwent incubation with anti-FLAG-PE Ab, and receptor expression was assessed through flow cytometry. Presented here is a representative overlay histogram illustrating MRGPRX4 expression.
Ref: Roy, Saptarshi, et al. "Angiogenic host defense peptide AG-30/5C and bradykinin B2 receptor antagonist icatibant are G protein biased agonists for MRGPRX2 in mast cells." The Journal of Immunology 202.4 (2019): 1229-1238.
Pubmed: 30651343
DOI: 10.4049/jimmunol.1801227
Research Highlights
Kotliar IB, et al. "Itch receptor MRGPRX4 interacts with the receptor activity-modifying proteins.." The Journal of biological chemistry, 2023.
Cholestatic itch, a distressing symptom commonly seen in liver diseases, has limited treatment options. Recent studies have identified Mas-related G protein-coupled receptor subtype X4 (MRGPRX4) as a bile acid receptor involved in cholestatic pruritus. Researchers have also found that GPCRs can interact with receptor activity-modifying proteins (RAMPs), which can influence GPCR function. Using advanced techniques, the study demonstrates a physical interaction between MRGPRX4 and RAMPs, particularly RAMP2, resulting in decreased signaling and surface expression of MRGPRX4. Additionally, the structure of the MRGPRX4-RAMP2 complex has been predicted using AlphaFold Multimer. These findings suggest that targeting the MRGPRX4-RAMP2 interaction may hold promise for future treatments of cholestatic itch.
Pubmed:
37003505
DOI:
10.1016/j.jbc.2023.104664
Levy C, et al. "New Treatment Paradigms in Primary Biliary Cholangitis.." Clinical gastroenterology and hepatology : the official clinical practice journal , 2023.
Primary biliary cholangitis (PBC) is a classic autoimmune disease characterized by chronic lymphocytic cholangitis and associated with various symptoms, including fatigue, itch, abdominal pain, and sicca complex. Despite the identification of female predominance, specific serum autoantibodies, and genetic risk factors, the current treatment approach primarily addresses cholestatic symptoms. Abnormal biliary epithelial homeostasis contributes to the disease, and therapies aimed at targeting this abnormality and inflammation are in development. Current first-line therapy is ursodeoxycholic acid, with the addition of obeticholic acid for those with residual cholestasis. Other agents under investigation include PPAR agonists, NOX inhibitors, and immunoregulatory therapies. The ultimate goal of PBC therapy is to promptly achieve normal serum test results and improve quality of life while preventing end-stage liver disease.
Pubmed:
36809835
DOI:
10.1016/j.cgh.2023.02.005
